D 150
Alternative Names: D-150Latest Information Update: 16 Jul 2024
At a glance
- Originator Chong Kun Dang
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 17 May 2024 Chong Kun Dang Pharmaceutical completes a phase I trial for Type 2 diabetes mellitus (In volunteers, Combination therapy) in South Korea (PO, Tablet) (NCT06483243)
- 04 Apr 2024 Chong Kun Dang Pharmaceutical initiates enrolment in a phase I trial for Type 2 diabetes mellitus (In volunteers, Combination therapy) in South Korea (PO, Tablet) (NCT06483243)
- 05 Sep 2023 Chong Kun Dang Pharmaceutical completes a phase I trial for Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT05741437)